| AASLD

Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

Read more about Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

Christian A. Hudert, Leon A. Adams, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU‐PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Phillip E. Melton, Trevor A. Mori, Stuart G. Snowden, Indra Mourik, Anita Vreugdenhil, Susanna Wiegand, Jake P.

The remarkable success of the vaccine for a killer virus: Hepatitis B

Read more about The remarkable success of the vaccine for a killer virus: Hepatitis B

Carla S. Coffin – 10 April 2022

Palliative care experience and perceived gaps in training among transplant hepatology fellows: A national survey

Read more about Palliative care experience and perceived gaps in training among transplant hepatology fellows: A national survey

Maureen P. Whitsett, Nneka N. Ufere, Arpan Patel, Judy A. Shea, Christopher A. Jones, Oren K. Fix, Marina Serper – 10 April 2022 – Despite the likely benefits of palliative care (PC) for patients with cirrhosis, physician experiences and perspectives about best practices are variable. We aimed to assess PC experience and gaps in training among transplant hepatology fellows. We conducted a national survey of all transplant hepatology fellows enrolled in accredited fellowship programs during the 2020–2021 academic year.

Risk of cardiovascular disease and loss in life expectancy in NAFLD

Read more about Risk of cardiovascular disease and loss in life expectancy in NAFLD

Ying Shang, Patrik Nasr, Linnea Widman, Hannes Hagström – 9 April 2022

P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis

Read more about P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis

Yahui Zhu, Li Gu, Xi Lin, Xinyi Zhou, Bingjun Lu, Cheng Liu, Yajun Li, Edward V. Prochownik, Michael Karin, Fubing Wang, Youjun Li – 9 April 2022

Reply

Read more about Reply

Vlad Ratziu – 8 April 2022

A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab–bevacizumab to avoid graft rejection?

Read more about A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab–bevacizumab to avoid graft rejection?

Edouard Larrey, Filomena Conti, Manon Allaire – 8 April 2022

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty

Read more about Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty

François Pattou, Guillaume Lasailly, Violeta Raverdy, Robert Caiazzo, Philippe Mathurin – 7 April 2022

Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

Read more about Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

Marta Alonso‐Peña, Ricardo Espinosa‐Escudero, Elisa Herraez, Oscar Briz, Maria Luisa Cagigal, Jesus M. Gonzalez‐Santiago, Aida Ortega‐Alonso, Conrado Fernandez‐Rodriguez, Luis Bujanda, Marta Calvo Sanchez, Delia D´Avola, Maria‐Carlota Londoño, Moises Diago, Jose C. Fernandez‐Checa, Carmen Garcia‐Ruiz, Raul J. Andrade, Frank Lammert, Jesus Prieto, Javier Crespo, Javier Juamperez, Alvaro Diaz‐Gonzalez, Maria J. Monte, Jose J. G. Marin – 7 April 2022

Operational tolerance is not always permanent: A 10‐year prospective study in pediatric liver transplantation recipients

Read more about Operational tolerance is not always permanent: A 10‐year prospective study in pediatric liver transplantation recipients

Laura J. Wozniak, Robert S. Venick, Bita V. Naini, Jason Scapa, Michelle J. Hickey, Maura Rossetti, Yael Korin, Elaine F. Reed, Douglas G. Farmer, Ronald W. Busuttil, Jorge H. Vargas, Sue V. McDiarmid – 7 April 2022 – Immunosuppression withdrawal can be safely performed in select liver transplantation recipients, but the long‐term outcomes and sustainability of tolerance have not been well studied.

Subscribe to